YOLFTbeta
Gyre Therapeutics Inc.

Gyre Therapeutics Inc.

GYRE · NASDAQ · Healthcare / Biotechnology

4.31USD+0.01 (+0.23%)

Price History

Full chart

Market Stats

Previous Close4.30
Open4.66
Day Range4.15 – 4.75
52-Week Range5.44 – 9.42
Volume281.30K
Market Cap779.35M
P/E (TTM)0.00
Forward P/E188.68
EPS-0.21
Dividend Yield0.00%
Beta4.83
50-Day Avg6.58
200-Day Avg7.10

About

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ying Luo Ph.D.
  • Employees625
  • Headquarters12730 High Bluff Drive, San Diego, CA, United States, 92130, USA
  • Websitehttps://www.gyretx.com

Leadership

  • Mr. Thomas W. Eastling M.D.Chief Financial Officer · b. 1959
  • Mr. Weiguo YeChief Operating Officer · b. 1978
  • Ms. Ruoyu ChenChief Information Officer · b. 1971
  • Dr. Ying Luo Ph.D.CEO, President & Director · b. 1965
  • Dr. Yue Xiong Ph.D.Chief Scientific Officer & Director
  • Mr. Joshua Bergmann J.D.General Counsel & Corporate Secretary
  • Seth Goldblum M.B.A.Senior Vice President of Corporate Development
  • Mr. Jialiang Wang Ph.D.Executive VP & GM
  • Jing Liu Ph.D.Senior Vice President of Platform Chemistry
  • Mark MarinoSenior Vice President of Clinical Development

Financials

Income Statement

Currency: USD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.70M2.29M2.46M3.74M1.18M27.54M11.58M20.09M25.06M85.71M97.64M57.86M3.63M1.81M1.75M399.00K1.02M6.00K-20.95M7.34M102.29M113.45M105.76M116.59M
Growth (%)-+34.23%+7.52%+52.09%-68.44%+2233.86%-57.96%+73.51%+24.78%+242.00%+13.91%-40.74%-93.73%-50.04%-3.47%-77.20%+155.14%-99.41%---64.97%+1293.98%+10.91%-6.78%+10.24%
Cost of Revenue-244.00K743.00K198.45K480.93K457.25K715.42K749.00K691.00K2.00M2.48M-6.56M5.27M5.96M10.55M173.00K149.00K146.00K9.16M7.67M4.79M4.64M3.88M5.42M
Gross Profit1.70M2.04M1.72M3.54M698.98K27.08M10.86M19.34M24.37M83.72M95.16M57.86M-2.93M-3.45M-4.21M-10.16M845.00K-143.00K-146.00K11.79M-332.00K97.50M108.81M101.87M111.17M
Gross Margin100.00%89.33%69.77%94.69%59.24%98.34%93.82%96.27%97.24%97.67%97.46%100.00%-80.68%-190.51%-240.46%-2545.36%83.01%-2383.33%-56.26%-4.52%95.31%95.91%96.33%95.35%
Operating Expense10.45M23.05M21.78M27.93M30.64M27.48M42.63M47.48M64.70M70.60M104.90M62.72M44.29M4.05M9.59M10.26M22.67M33.68M57.13M69.16M83.39M88.29M176.04M85.64M99.68M
Operating Income-8.75M-21.00M-20.06M-24.39M-29.94M-403.69K-31.77M-28.14M-40.33M13.12M-9.74M-4.86M-47.22M-7.51M-13.80M-20.42M-21.82M-33.82M-57.28M-57.37M-83.73M9.20M-67.23M16.23M11.49M
Operating Margin-513.86%-918.77%-816.27%-652.51%-2537.54%-1.47%-274.46%-140.12%-160.90%15.30%-9.98%-8.40%-1301.07%-414.18%-788.69%-5117.29%-2143.61%-563700.00%--273.87%-1140.99%9.00%-59.26%15.35%9.86%
EBITDA-8.75M-21.00M-20.06M-23.13M-29.14M417.23K-30.86M-26.34M-38.49M15.11M-7.26M-2.65M-46.76M-6.83M-12.81M-20.03M-21.65M-33.82M-55.03M-56.10M-87.64M10.54M20.33M17.82M16.96M
EBITDA Margin-513.86%-918.77%-816.27%-618.62%-2469.47%1.52%-266.63%-131.16%-153.58%17.63%-7.44%-4.58%-1288.56%-376.67%-732.23%-5019.80%-2126.62%-563700.00%--267.82%-1194.37%10.31%17.92%16.85%14.54%
Net Income-7.30M-21.07M-19.39M-24.03M-28.99M2.10M-28.07M-25.66M-39.40M10.90M-8.53M-7.00M-46.70M-32.62M-14.76M-16.95M-21.56M-30.05M-55.18M-55.54M-87.93M2.30M-92.93M12.09M5.03M
Net Income Margin-428.77%-921.78%-789.06%-642.67%-2457.08%7.61%-242.51%-127.76%-157.23%12.72%-8.74%-12.09%-1286.99%-1799.39%-843.54%-4246.87%-2117.98%-500916.67%--265.14%-1198.32%2.25%-81.92%11.43%4.31%
R&D8.15M16.24M18.18M22.77M24.25M21.79M34.62M40.98M40.18M64.55M95.22M49.09M38.84M5.27M5.96M11.55M12.85M21.47M43.86M52.98M64.57M16.69M13.78M12.02M13.70M
R&D as % of Total Revenue478.68%710.59%739.59%609.11%2055.35%79.12%299.06%204.04%160.32%75.30%97.52%84.84%1070.27%290.51%340.46%2895.99%1261.98%357900.00%-252.89%879.99%16.31%12.15%11.37%11.75%
Interest Expense---132.75K225.00K84.07K137.91K251.00K217.00K153.00K132.00K86.00K53.00K23.00K1.48M-----220.96K717.00K---
Interest Expense % of Total Revenue---3.55%19.07%0.31%1.19%1.25%0.87%0.18%0.14%0.15%1.46%1.27%84.46%-----3.01%0.70%---

Balance Sheet

Currency: USD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets24.40M54.38M47.39M58.20M28.00M81.37M98.96M98.55M319.38M262.79M258.13M189.58M145.87M112.00M69.52M38.09M39.51M124.92M98.55M94.85M55.66M84.75M116.54M125.41M166.13M
Total Liabilities-2.09M1.46M181.17M190.48M16.37M47.38M41.18M250.39M170.94M83.84M13.66M11.26M2.91M38.10M22.02M8.74M4.97M30.22M18.78M14.57M12.54M102.59M27.00M23.85M
Total Equity-38.27M-63.34M-90.80M-122.97M-162.48M65.00M51.58M57.37M68.99M91.85M174.29M175.91M134.61M109.08M31.43M16.07M30.77M119.94M68.34M76.07M41.09M42.52M-15.83M63.32M106.03M
Cash---53.08M24.85M41.74M53.40M51.20M83.91M165.85M107.28M82.24M54.48M56.43M29.10M10.26M14.47M31.21M15.37M30.36M44.35M25.18M33.51M11.81M37.07M
Total Debt-2.09M1.46M4.56M2.19M1.41M2.60M4.80M3.41M3.06M3.23M1.99M1.14M-33.74M19.40M5.08M-1.80M1.64M2.38M613.00K409.00K1.60M939.00K
Net Debt-2.09M1.46M-48.52M-22.66M-40.33M-50.80M-46.40M-80.50M-162.79M-104.06M-80.25M-53.35M-56.43M4.65M9.14M-9.39M-31.21M-13.57M-28.72M-41.96M-24.56M-33.10M-10.21M-36.13M

Cash Flow

Currency: USD2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-25.04M-26.25M-9.89M24.84M-28.26M-24.27M138.30M-83.72M-64.24M-40.61M-34.48M-19.12M-18.47M-19.94M-28.55M-43.61M-55.05M-83.75M10.68M25.89M-3.64M1.01M
Investing Cash Flow30.56M-250.25K-13.27M-26.29M-5.52M9.80M-62.80M-57.67M39.82M13.41M33.86M37.36M-1.31M-11.25M-71.32M27.39M9.66M48.19M-13.81M-19.76M-19.88M-474.00K
Financing Cash Flow35.94M-1.73M40.05M13.11M31.58M47.18M6.45M82.81M-626.00K-552.00K5.01M9.31M948.00K35.40M111.33M327.00K60.38M49.55M-45.01M2.50M2.10M24.38M
Capital Expenditure660.62K250.25K1.08M4.94M2.05M200.00K3.31M1.43M333.00K92.00K4.00K272.00K468.00K23.00K376.00K64.00K267.00K839.00K5.00M8.59M3.13M1.19M
Free Cash Flow-25.70M-26.50M-10.97M19.89M-30.31M-24.47M134.99M-85.15M-64.57M-40.70M-34.49M-19.39M-18.94M-19.96M-28.93M-43.68M-55.31M-84.59M5.68M17.31M-6.77M-180.00K
Dividends Paid-------------3.95M---045.03M---
FCF to OCF102.64%100.95%110.88%80.10%107.26%100.82%97.61%101.71%100.52%100.23%100.01%101.42%102.53%100.12%101.32%100.15%100.49%101.00%53.19%66.84%185.91%-17.82%
Dividend Paid to FCF--------------19.79%---0.00%792.94%---

Earnings

Report DateMay 25, 2006Aug 9, 2006Nov 10, 2006Feb 23, 2007May 10, 2007Aug 8, 2007Nov 9, 2007Feb 13, 2008May 7, 2008Aug 6, 2008Nov 7, 2008Feb 13, 2009May 11, 2009Aug 6, 2009Nov 6, 2009Feb 12, 2010May 6, 2010Aug 5, 2010Nov 5, 2010Feb 11, 2011May 6, 2011Aug 5, 2011Nov 2, 2011Feb 22, 2012May 4, 2012Aug 8, 2012Nov 7, 2012Feb 14, 2013May 7, 2013Aug 6, 2013Nov 5, 2013Feb 13, 2014May 7, 2014Aug 6, 2014Nov 5, 2014Feb 12, 2015May 6, 2015Jul 31, 2015Nov 4, 2015Mar 10, 2016May 4, 2016Jul 29, 2016Nov 3, 2016Mar 9, 2017May 4, 2017Aug 3, 2017Nov 2, 2017Mar 1, 2018May 3, 2018Aug 2, 2018Nov 1, 2018Mar 7, 2019May 2, 2019Aug 1, 2019Nov 7, 2019Feb 20, 2020May 11, 2020Aug 6, 2020Nov 5, 2020Mar 4, 2021May 6, 2021Aug 5, 2021Nov 12, 2021Mar 31, 2022May 9, 2022Aug 15, 2022Nov 23, 2022Mar 9, 2023May 4, 2023Aug 3, 2023Oct 26, 2023Mar 27, 2024May 9, 2024Aug 12, 2024Nov 4, 2024Mar 24, 2025May 9, 2025Aug 11, 2025Nov 7, 2025Mar 31, 2026May 7, 2026Aug 7, 2026Nov 6, 2026
EPS Estimate-------------------------------40.60-40.95-38.85-34.13-23.10-18.900.00--0.31---4.65-6.83-5.63-6.10-1.46-1.32-1.53-0.92-0.62-0.59-0.75-1.08-1.11-1.160.17-0.37-0.86-0.81-0.86-0.58-0.69-0.66-0.59-0.46-0.24-0.10-0.10-0.07-0.07-0.75-0.60---0.040.030.03-0.020.05-0.07-0.08-0.14
EPS Actual-431.82-519.75-400.831309.62-394.51-679.67-577.64-587.91-382.03-430.20-482.87-342.52-295.06-608.9677.98-1514.29366.86197.55129.76-118.65652.13-115.70-427.23-488.12105.20678.53-370.50-743.69-377.91-579.43-0.38-0.40-0.44-0.24-0.14-0.140.00-201.53-210.04-100.98-70.71-0.42-90.00-4.65-4.57-1.52-20.10-1.25-8.40-8.10-9.60-13.65-18.90-17.25-15.90-18.45-4.20-14.40-10.95-12.90-11.85-9.60-12.00-9.75-6.9024.60-2.40-19.050.15-1.05-1.050.000.030.030.01-0.000.000.000.030.05-0.10-0.12-
Surprise------------------------------99.06%99.02%98.87%99.30%99.39%99.26%---67653.48%--90.97%-1217.72%17.41%25.08%-4.11%-1422.73%18.30%-813.04%-1206.45%-1527.12%-1720.00%-1650.00%-1454.05%-1270.69%-10952.94%-1035.14%-1574.42%-1257.38%-1395.65%-1951.95%-1281.30%-1718.18%-1559.57%-1410.84%10140.82%-2300.00%-18042.86%314.29%-1400.00%-40.00%100.00%----102.75%-85.67%-92.67%250.00%0.21%-42.86%-50.00%-
Timing----------------------------------------------------------------------After-hours-After-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-market-Pre-market--

Key Statistics & Ratios

Market Cap779.35M
Enterprise Value714.86M
Trailing P/E0.00
Forward P/E188.68
Price / Sales7.10
Price / Book7.28
EPS-0.21
Book Value1.02
Revenue (TTM)109.82M
Gross Profit (TTM)103.01M
EBITDA-12.13M
Profit Margin-19.33%
Operating Margin-47.62%
Return on Equity-17.44%
Return on Assets-5.42%
Shares Outstanding106.03M
Shares Float35.94M
Beta4.83
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 18.67
  • Strong Buy
    1

Ownership Breakdown

Institutions
8.24%
Insiders
74.40%
Retail / Other
17.36%

Top Institutional Holders

  • Vanguard Capital Management, LLC
    984.20K0.93%
  • Octagon Capital Advisors LP
    954.42K0.90%
  • BlackRock Inc
    758.63K0.72%
  • Geode Capital Management, LLC
    431.41K0.41%
  • State Street Corp
    216.33K0.20%
  • SBI Securities Co Ltd
    170.84K0.16%
  • Charles Schwab Investment Management Inc
    165.24K0.16%
  • Vanguard Fiduciary Trust Co
    137.68K0.13%
  • Northern Trust Corp
    133.84K0.13%
  • The Goldman Sachs Group Inc
    73.12K0.07%
  • Vanguard Portfolio Management, LLC
    69.81K0.07%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    614.65K0.58%
  • iShares Russell 2000 ETF
    388.44K0.37%
  • Fidelity Small Cap Index
    200.15K0.19%
  • iShares Russell 2000 Growth ETF
    121.65K0.11%
  • Fidelity Extended Market Index
    110.87K0.10%
  • Vanguard Russell 2000 ETF
    105.76K0.10%
  • Schwab US Small-Cap ETF™
    99.03K0.09%
  • Fidelity Nasdaq Composite Index
    62.21K0.06%
  • Schwab Small Cap Index
    44.88K0.04%

Dividends

20231×
3.60Jan 13, 2023
20221×
21.45Sep 21, 2022
20151×
896.17Aug 20, 2015

Stock Splits

  • Oct 31, 20231:15
  • Feb 13, 20171:15
  • Aug 21, 20151:7